FDA's evaluation concluded that the criteria weighed against placement on the list, citing inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, lack of clinical effectiveness data for any approved use, and absence of published human exposure data for the proposed subcutaneous and topical routes
Transient breathing discomfort or mild bronchospasm reported in some individuals, particularly those with asthma or sensitive airways
I guide patients through their journey with GLP-1 from day one
Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle
In autoimmune hair loss conditions like alopecia areata where the immune system mistakenly attacks hair follicles T1 helps recalibrate immune function rather than simply suppressing it
[Q] Vikas Shah: My worry is that when a treatment is this effective, it sometimes almost becomes part of celebrity culture, of lifestyle culture and its very difficult to moderate how consumers interact with medicine